#South Korea #Seoul #Co-Diagnostics #PCR platform #Medical Korea

Co-Diagnostics to Present at Medical Korea 2026

Co-Diagnostics, Inc. is set to make a significant presence at the upcoming Medical Korea 2026, an important conference focusing on global healthcare and medical tourism. Scheduled to take place from March 19 to 22 in the bustling capital of South Korea, Seoul, this event will gather over 6,000 participants from more than 50 countries, creating a vibrant platform for networking and collaboration.

Company Overview

Co-Diagnostics, often referred to as Co-Dx, is a pioneering molecular diagnostics company specializing in the development and commercialization of advanced diagnostic technologies. Its innovative, patented platform allows for the creation of molecular diagnostic tests, primarily targeting the detection of infectious diseases through nucleic acid analysis.

Participation in Medical Korea 2026

At the conference, Co-Dx will join forces with the World Trade Center (WTC) Utah, the Utah Governor's Office of Economic Opportunity (GOEO), BioUtah, and various legislative and industry leaders. Co-Diagnostics plans to engage in a healthcare business roundtable on March 19, where it will present its upcoming Co-Dx PCR point-of-care platform. This exciting technology promises to revolutionize how infectious diseases are diagnosed, enabling faster and more efficient testing.

The key focus of this year's conference is "AI-Powered Global Healthcare Bringing the Future and the World Closer". Co-Dx will showcase its innovative point-of-care solutions at the State of Utah booth, where attendees can learn how these advancements align with the conference's goal of fostering international healthcare collaborations.

Significance of the Event

David Carlebach, COO of WTC Utah, emphasizes the importance of South Korea as a key partner for Utah, particularly in enhancing trade relationships and investments. By establishing a dedicated team in Seoul, WTC Utah aims to facilitate partnerships within South Korea's dynamic healthcare ecosystem. Medical Korea serves as an excellent venue to promote collaboration in healthcare and life sciences between Utah and South Korea, and Co-Dx's participation is pivotal in strengthening these ties.

Furthermore, this trade mission is supported in part by a grant from WTC Utah, highlighting the organization's commitment to connecting Utah companies with international partners and resources. The conference, marking its 16th annual gathering, promises to be a key event for industry leaders, government officials, and innovators looking to expand their networks and explore emerging medical technologies.

Forward-Looking Statements

It’s important to note that the Co-Dx PCR platform, including its various components such as the PCR Home®, PCR Pro®, and related tests, is currently under review by the FDA and other regulatory bodies. These products are not available for sale as they await clearance.

In summary, Co-Diagnostics' involvement in Medical Korea 2026 highlights their commitment to advancing healthcare solutions on a global scale. By leveraging cutting-edge technology and fostering international collaborations, Co-Dx is poised to make a lasting impact in the field of molecular diagnostics.

For more information on Co-Diagnostics and its innovative solutions, visitors can reach out to their representatives at the Utah booth during the event. Stay tuned as the journey towards revolutionizing healthcare continues with Co-Dx leading the way.